Glassman’s Recent Move: A Quiet Buy on a Hot Stock
On September 9, 2026, Glassman Robert, a director of Pharvaris NV, purchased 8,000 shares of the company at $32.00 each through a scheduled 10(b)(5) plan. The transaction, executed at a price only 0.01% below the closing market price of $32.35, signals confidence in a stock that has already earned a 9.88% monthly gain and a 64 % yearly rally. With a 52‑week high of €38.25, Pharvaris is still trading below its all‑time peak, yet its earnings‑to‑price ratio of –13.27 suggests investors are still awaiting a breakthrough in the clinical pipeline.
Implications for Investors
Glassman’s action is a bullish sign for investors, especially given the high social‑media buzz (152 %) and a positive sentiment score (+44). The director’s purchase is part of a broader pattern: between May and August, he has repeatedly traded both shares and options, often buying at lower valuations and selling at premium prices. The most recent sale of 8,000 shares by the same director a day earlier (at $37.55) illustrates a strategic use of the 10(b)(5) plan to capture short‑term price appreciation while preserving long‑term upside. For shareholders, this means a potential uptick in liquidity and a subtle endorsement of management’s trajectory.
What the Move Means for Pharvaris’s Future
Pharvaris is a clinical‑stage company focused on B2 receptor antagonists. The company’s pipeline remains in early development, but the recent insider activity—both purchases and sales—indicates that executives are comfortable with the current valuation while awaiting data. The 10(b)(5) plan ensures compliance with insider‑trading rules, giving investors confidence that any future sales will be orderly. If the clinical program progresses, the stock could see another significant rally, and insiders like Glassman are positioned to benefit.
Glassman Robert: A Transaction Profile
Glassman has a history of disciplined insider trading. Over the past months he has bought roughly 20,500 shares at $22.31–$29.83 and sold 10,500–15,167 shares at $29.82–$29.83, reflecting a preference for buying low and selling high. He has also exercised and sold options, capitalizing on the 10(b)(5) plan to lock in gains without breaching market‑timing regulations. His activity shows a balanced approach—maintaining a significant shareholding while generating liquidity through scheduled sales. This pattern suggests he views Pharvaris as a long‑term investment while leveraging short‑term price movements for capital efficiency.
Investor Takeaway
Glassman’s recent purchase, coupled with his historical trading pattern, points to a director who trusts Pharvaris’s long‑term prospects but also manages exposure strategically. For investors, this insider confidence—aligned with robust social‑media buzz and a strong upward trend—could serve as a catalyst for continued interest in the stock, especially as the company moves closer to regulatory milestones in its B2 antagonist program.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-09-09 | Glassman Robert () | Buy | 8,000.00 | 20.00 | Common Stock |
| 2026-09-09 | Glassman Robert () | Sell | 8,000.00 | 37.55 | Common Stock |
| 2026-09-09 | Glassman Robert () | Sell | 8,000.00 | N/A | Stock Option (Right to Buy) |
